Urolithin A: What Human Trials Say About Mitophagy

Urolithin A has earned more attention than the average supplement ingredient because human trials have measured changes in muscle performance, mitochondrial biomarkers, and—most unexpectedly—immune-cell populations. The evidence supports a narrower claim than the marketing: crystalline urolithin A can affect measurable biology over weeks to months. It does not yet show that it prevents immune aging, treats muscular dystrophy, or extends healthy lifespan.

Urolithin A is a metabolite that gut bacteria can make from ellagitannins, compounds found in foods such as pomegranate, berries, and walnuts. Many people may not convert those foods into urolithin A reliably because production depends on the microbiome. Crystalline supplemental urolithin A bypasses that variable and produces reproducible blood exposure in human studies. A 2024 systematic review identified five human studies totaling 250 participants, which is encouraging but still a small clinical literature.

The immune result is real, but it is not an immune-rejuvenation verdict

The most surprising human finding comes from the MitoImmune trial, a 28-day randomized, placebo-controlled study of 50 adults given 1,000 mg of urolithin A or placebo. In the 2025 Nature Aging trial, urolithin A significantly increased circulating naive CD8+ T cells and total lymphocyte counts relative to placebo.

Naive CD8+ T cells are cells that have not yet encountered their target antigen. Their numbers and function tend to decline with age, so an increase is biologically interesting. The investigators proposed that mitophagy—the selective clearance of damaged mitochondria—may activate Wnt/TCF1 signaling and support a fatty-acid-oxidation-dependent, longer-lived naive phenotype. That is a plausible mechanistic account, not proof that this pathway explains every observed immune effect in people.

The trial also supplies an important corrective. Urolithin A did not increase the percentage of T memory stem cells, or TSCM cells, in the human participants after 28 days. Earlier mouse experiments and ex vivo CAR-T-cell work from the same research group had pointed in that direction. The human result confirmed naive CD8+ expansion but failed to confirm the TSCM claim. Anyone presenting TSCM expansion as an established benefit of oral urolithin A is getting ahead of the trial.

Safety over 28 days looked reassuring: there were nine adverse events in total, four in the urolithin A group and five with placebo, mostly upper respiratory infections. The study reported no clinically significant kidney- or liver-function changes. That supports short-term tolerability in this small sample. It cannot establish long-term safety, immune protection against infection, or a reduction in age-related disease.

Muscle trials provide the strongest functional evidence

The immune study would be easier to dismiss as an isolated cell-count result if muscle trials had not already found changes in physical function and mitochondrial markers. In the ATLAS trial, 88 sedentary, overweight adults aged 40 to 64 were randomized for four months to placebo, 500 mg of urolithin A, or 1,000 mg daily. The 2022 Cell Reports Medicine trial reported improved muscle strength and exercise performance alongside evidence from skeletal-muscle biopsies of increased mitophagy and mitochondrial proteins.

The reported strength differences were similar at both doses. Hamstring peak torque improved by about 12% with 500 mg and 9.8% with 1,000 mg versus placebo; knee-flexion maximum torque improved by about 10.6% and 10.5%, respectively. The available report does not provide confidence intervals for these figures, so readers cannot judge their precision from the published summary here. Still, the near-match between doses argues against assuming that more is better for these muscle endpoints.

Participants also had lower plasma acylcarnitines, metabolites that can rise when mitochondrial fatty-acid oxidation is inefficient. That result fits the mitophagy hypothesis: clearing dysfunctional mitochondria could improve fat oxidation. It remains a biomarker result, not direct proof that mitochondrial cleanup caused the strength improvement. Biology rarely hands out a single culprit with a signed confession.

The ATLAS investigators reported no meaningful differences among placebo, 500 mg, and 1,000 mg groups in vital signs, blood chemistry, hematology, or urinalysis over four months. However, researchers at Amazentis SA, the developer of crystalline urolithin A sold as Mitopure, led the trial. Industry involvement does not erase randomized results, but it raises the usual risk that early effect sizes will look larger than they do in independent replication.

An independent four-month randomized trial helps with that concern, although it studied a different outcome and population. In 66 older adults, the 2022 JAMA Network Open trial found improved muscle endurance and mitochondrial-health biomarkers with urolithin A. It supports the idea that the compound can affect muscle-related outcomes beyond the middle-aged ATLAS population. It does not establish the same torque effect in adults 65 and older, nor does ATLAS establish an endurance benefit in its own participants. The studies point in the same general direction without measuring identical things.

Why food is not a dependable substitute

Ellagitannin-rich foods remain nutritious for reasons that have little to do with urolithin A, but eating pomegranate or walnuts does not guarantee urolithin A exposure. Gut microbes must convert dietary precursors into the metabolite, and the relevant human studies do not quantify how many people fail to produce it. The systematic review confirms human bioavailability of supplemental urolithin A, while the clinical trials used crystalline material rather than an ellagitannin food intervention.

That distinction matters for anyone trying to copy trial conditions. The evidence supports the doses actually tested: 500 mg and 1,000 mg daily for muscle-related outcomes over four months, and 1,000 mg daily for immune-cell outcomes over 28 days. It does not show that food-derived precursor intake produces the same exposure or effects. Nor does it show that 500 mg would reproduce the immune finding, because the immune trial tested only 1,000 mg.

Duchenne muscular dystrophy is a mechanism story, not a treatment claim

The most compelling disease-model work comes from Duchenne muscular dystrophy (DMD), where progressive muscle degeneration involves both damaged mature muscle fibers and failure of muscle stem cells to sustain repair. In the 2021 Science Translational Medicine study, researchers found impaired mitophagy in skeletal muscle and muscle stem cells from mdx mice, with reduced mitophagy-gene expression also documented in DMD patient biopsy tissue.

Urolithin A restored mitophagy in C. elegans, mdx mice, and primary human DMD myoblasts. In the mouse work, it improved skeletal-muscle respiratory capacity, muscle stem-cell regenerative function, muscle function, and survival. The stem-cell result matters because exhausted muscle stem cells contribute to DMD's declining capacity for regeneration.

None of this demonstrates clinical benefit in people with DMD. Human biopsy tissue can show that a disease-relevant pathway is impaired; it cannot tell us that correcting the pathway with a supplement will preserve walking ability, respiratory function, or survival. Neuromuscular drug development has a long record of preclinical results that did not survive human testing. Urolithin A has no human interventional DMD trial.

Heart failure and other extrapolations remain unsettled

A randomized, double-blind, crossover, placebo-controlled trial has examined urolithin A in patients with heart failure and reduced ejection fraction, as described by Jamialahmadi and colleagues in 2024. Heart failure has mitochondrial dysfunction, making it a reasonable setting to study the compound. The available publication summary does not provide effect-size details, so it cannot support a quantitative clinical claim here.

Even a favorable functional result in heart failure would not by itself prove that mitophagy caused it. Reduced-ejection-fraction heart failure also involves neurohormonal signaling, inflammation, structural remodeling, comorbid illness, and altered metabolism. The crossover design adds its own interpretive questions. This is an interesting extension of the hypothesis, not confirmation that urolithin A treats cardiac disease.

What a careful buyer can conclude

Three human randomized trials provide the useful core: four months of urolithin A improved muscle strength measures in sedentary, overweight middle-aged adults; four months improved muscle endurance and mitochondrial biomarkers in older adults; and 28 days increased naive CD8+ T cells and total lymphocytes in a small immune-aging trial. Across those studies, reported short-term safety was favorable.

The limits deserve equal weight. The main trials were small, single-center studies, and placebo-controlled follow-up extends no longer than four months. Benefits may persist, plateau, disappear after stopping, or differ in healthy athletes, frail older adults, and people with chronic disease. Independent replication remains limited. DMD has preclinical support but no human efficacy data, and osteoarthritis claims should not be treated as established on the basis of these trials.

For muscle-focused use, 500 mg daily of crystalline urolithin A is the lowest dose with reported benefit in the ATLAS trial. The immune finding used 1,000 mg, so a lower immune dose remains untested. The evidence supports measured short-term effects, not a promise to reset your mitochondria—or your immune system—to factory settings.